PROCLIPI: a study aiming to identify factors important in predicting the outcome of cutaneous (skin) lymphomas, mycosis fungoides and Sezary syndrome
There is no treatment in this study. The researchers need your permission for your doctor to share information from your medical records for research.
Initial findings from this study have been published, but it is still recruiting new participants.
Trial aim and background
The aim of the study is to gather the information needed to develop an improved ‘prognostic index’ for the rare cutaneous (skin) lymphomas, mycosis fungoides and Sézary syndrome. These are both types of T-cell lymphomas that start in the skin.
Cutaneous T-cell lymphomas can be very variable and many people only ever have a mild form that is not life-threatening and can be kept under control for many years. Only a few people go on to develop a more serious form.
A prognostic index is a group of factors that doctors look at when someone is first diagnosed. Looking at these together can help a specialist to tell which people are likely to do well and which not so well. In some conditions, including cutaneous T-cell lymphomas, the doctor can use a prognostic index to see who needs treating earlier or needs more intensive treatment and who doesn’t. You may hear doctors refer to these as high or low risk groups.
If you join, your doctor sends details of your treatment, your test results and how you are to the study team for analysis. Your information is de-identified so you cannot be recognised (no name, date of birth or address is shared).
Who can enter
Patients who have been diagnosed with mycosis fungoides or Sézary syndrome in the past 6 months may be eligible for this trial.
Locations
Recruitment is taking place at University Hospitals Birmingham.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT02848274
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.